Search

Your search keyword '"Chau, Nguyen Hoang"' showing total 34 results
Start Over Author "Chau, Nguyen Hoang"
34 results on '"Chau, Nguyen Hoang"'

2. The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial

Author

Thriemer, Kamala, Commons, Robert James, Rajasekhar, Megha, Degaga, Tamiru Shibiru, Chand, Krisin, Chau, Nguyen Hoang, Assefa, Ashenafi, Naddim, Mohammad Nader, Pasaribu, Ayodhia Pitaloka, Rahim, Awab Ghulam, Sutanto, Inge, Hien, Tran Tinh, Hailu, Asrat, Hasanzai, Mohammad Anwar, Ekawati, Lenny L., Woyessa, Adugna, Teferi, Tedla, Waithira, Naomi, Taylor, Walter R. J., Ley, Benedikt, Dondorp, Arjen, Baird, J. Kevin, White, Nicholas J., Day, Nicholas P., Price, Ric N., Simpson, Julie A., and von Seidlein, Lorenz

Published
2023
Full Text
View/download PDF

3. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis

Author

Adhikari, Bipin, Anstey, Nicholas M, Assefa, Ashenafi, Boyd, Sarah C, Chau, Nguyen Hoang, Day, Nicholas PJ, Degaga, Tamiru Shibiru, Dondorp, Arjen M, Erhart, Annette, Ferreira, Marcelo Urbano, Ghimire, Prakash, Green, Justin A, Koh, Gavin CKW, Mekuria, Asrat Hailu, Mueller, Ivo, Naadim, Mohammad Nader, Nelwan, Erni J, Nosten, Francois, Price, David J, Sattabongkot, Jetsumon, Stepniewska, Kasia, von Seidlein, Lorenz, William, Timothy, Woodrow, Charles J, Woyessa, Adugna, Commons, Robert J, Rajasekhar, Megha, Edler, Peta, Abreha, Tesfay, Awab, Ghulam R, Baird, J Kevin, Barber, Bridget E, Chu, Cindy S, Cui, Liwang, Daher, André, Gonzalez-Ceron, Lilia, Grigg, Matthew J, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Lidia, Kartini, Llanos-Cuentas, Alejandro, Longley, Rhea J, Pereira, Dhelio B, Pasaribu, Ayodhia P, Pukrittayakamee, Sasithon, Rijal, Komal R, Sutanto, Inge, Taylor, Walter R J, Thanh, Pham V, Thriemer, Kamala, Vieira, José Luiz F, Watson, James A, Zuluaga-Idarraga, Lina M, White, Nicholas J, Guerin, Philippe J, Simpson, Julie A, and Price, Ric N

Published
2024
Full Text
View/download PDF

4. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis

Author

Adhikari, Bipin, Alam, Mohammad Shafiul, Anstey, Nicholas M, Assefa, Ashenafi, Boyd, Sarah C, Chau, Nguyen Hoang, Day, Nicholas PJ, Degaga, Tamiru Shibiru, Dondorp, Arjen M, Ferreira, Marcelo Urbano, Ghimire, Prakash, Green, Justin A, Khan, Wasif Ali, Koh, Gavin CKW, Mekuria, Asrat Hailu, Naadim, Mohammad Nader, Nelwan, Erni J, Nosten, Francois, Pasaribu, Ayodhia Pitaloka, Price, David J, Stepniewska, Kasia, von Seidlein, Lorenz, William, Timothy, Woodrow, Charles J, Woyessa, Adugna, Rajasekhar, Megha, Simpson, Julie A, Ley, Benedikt, Edler, Peta, Chu, Cindy S, Abreha, Tesfay, Awab, Ghulam R, Baird, J Kevin, Bancone, Germana, Barber, Bridget E, Grigg, Matthew J, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Llanos-Cuentas, Alejandro, Pukrittayakamee, Sasithon, Rijal, Komal R, Saravu, Kavitha, Sutanto, Inge, Taylor, Walter R J, Thriemer, Kamala, Watson, James A, Guerin, Philippe J, White, Nicholas J, Price, Ric N, and Commons, Robert J

Published
2024
Full Text
View/download PDF

5. Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination.

Author

Jacob, Christopher G, Thuy-Nhien, Nguyen, Mayxay, Mayfong, Maude, Richard J, Quang, Huynh Hong, Hongvanthong, Bouasy, Vanisaveth, Viengxay, Ngo Duc, Thang, Rekol, Huy, van der Pluijm, Rob, von Seidlein, Lorenz, Fairhurst, Rick, Nosten, François, Hossain, Md Amir, Park, Naomi, Goodwin, Scott, Ringwald, Pascal, Chindavongsa, Keobouphaphone, Newton, Paul, Ashley, Elizabeth, Phalivong, Sonexay, Maude, Rapeephan, Leang, Rithea, Huch, Cheah, Dong, Le Thanh, Nguyen, Kim-Tuyen, Nhat, Tran Minh, Hien, Tran Tinh, Nguyen, Hoa, Zdrojewski, Nicole, Canavati, Sara, Sayeed, Abdullah Abu, Uddin, Didar, Buckee, Caroline, Fanello, Caterina I, Onyamboko, Marie, Peto, Thomas, Tripura, Rupam, Amaratunga, Chanaki, Myint Thu, Aung, Delmas, Gilles, Landier, Jordi, Parker, Daniel M, Chau, Nguyen Hoang, Lek, Dysoley, Suon, Seila, Callery, James, Jittamala, Podjanee, Hanboonkunupakarn, Borimas, Pukrittayakamee, Sasithon, Phyo, Aung Pyae, Smithuis, Frank, Lin, Khin, Thant, Myo, Hlaing, Tin Maung, Satpathi, Parthasarathi, Satpathi, Sanghamitra, Behera, Prativa K, Tripura, Amar, Baidya, Subrata, Valecha, Neena, Anvikar, Anupkumar R, Ul Islam, Akhter, Faiz, Abul, Kunasol, Chanon, Drury, Eleanor, Kekre, Mihir, Ali, Mozam, Love, Katie, Rajatileka, Shavanthi, Jeffreys, Anna E, Rowlands, Kate, Hubbart, Christina S, Dhorda, Mehul, Vongpromek, Ranitha, Kotanan, Namfon, Wongnak, Phrutsamon, Almagro Garcia, Jacob, Pearson, Richard D, Ariani, Cristina V, Chookajorn, Thanat, Malangone, Cinzia, Nguyen, T, Stalker, Jim, Jeffery, Ben, Keatley, Jonathan, Johnson, Kimberly J, Muddyman, Dawn, Chan, Xin Hui S, Sillitoe, John, Amato, Roberto, Simpson, Victoria, Gonçalves, Sonia, Rockett, Kirk, Day, Nicholas P, Dondorp, Arjen M, Kwiatkowski, Dominic P, and Miotto, Olivo

Subjects
asia, drug resistance, epidemiology, genetic surveillance, global health, infectious disease, malaria, microbiology, Biochemistry and Cell Biology
Abstract

BackgroundNational Malaria Control Programmes (NMCPs) currently make limited use of parasite genetic data. We have developed GenRe-Mekong, a platform for genetic surveillance of malaria in the Greater Mekong Subregion (GMS) that enables NMCPs to implement large-scale surveillance projects by integrating simple sample collection procedures in routine public health procedures.MethodsSamples from symptomatic patients are processed by SpotMalaria, a high-throughput system that produces a comprehensive set of genotypes comprising several drug resistance markers, species markers and a genomic barcode. GenRe-Mekong delivers Genetic Report Cards, a compendium of genotypes and phenotype predictions used to map prevalence of resistance to multiple drugs.ResultsGenRe-Mekong has worked with NMCPs and research projects in eight countries, processing 9623 samples from clinical cases. Monitoring resistance markers has been valuable for tracking the rapid spread of parasites resistant to the dihydroartemisinin-piperaquine combination therapy. In Vietnam and Laos, GenRe-Mekong data have provided novel knowledge about the spread of these resistant strains into previously unaffected provinces, informing decision-making by NMCPs.ConclusionsGenRe-Mekong provides detailed knowledge about drug resistance at a local level, and facilitates data sharing at a regional level, enabling cross-border resistance monitoring and providing the public health community with valuable insights. The project provides a rich open data resource to benefit the entire malaria community.FundingThe GenRe-Mekong project is funded by the Bill and Melinda Gates Foundation (OPP11188166, OPP1204268). Genotyping and sequencing were funded by the Wellcome Trust (098051, 206194, 203141, 090770, 204911, 106698/B/14/Z) and Medical Research Council (G0600718). A proportion of samples were collected with the support of the UK Department for International Development (201900, M006212), and Intramural Research Program of the National Institute of Allergy and Infectious Diseases.

Published
2021

6. Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis

Author

Fadilah, Ihsan, primary, Commons, Robert J, additional, Chau, Nguyen Hoang, additional, Chu, Cindy S, additional, Day, Nicholas PJ, additional, Koh, Gavin CKW, additional, Green, Justin A, additional, Lacerda, Marcus VG, additional, Llanos-Cuentas, Alejandro, additional, Nelwan, Erni J, additional, Nosten, Francois, additional, Pasaribu, Ayodhia Pitaloka, additional, Sutanto, Inge, additional, Taylor, Walter RJ, additional, Thriemer, Kamala, additional, Price, Ric N, additional, White, Nicholas J, additional, Baird, J Kevin, additional, and Watson, James A, additional

Published
2024
Full Text
View/download PDF

7. Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial

Author

Peto, Thomas J, Tripura, Rupam, Callery, James J, Lek, Dysoley, Nghia, Ho Dang Trung, Nguon, Chea, Thuong, Nguyen Thi Huyen, van der Pluijm, Rob W, Dung, Nguyen Thi Phuong, Sokha, Meas, Van Luong, Vo, Long, Le Thanh, Sovann, Yok, Duanguppama, Jureeporn, Waithira, Naomi, Hoglund, Richard M, Chotsiri, Palang, Chau, Nguyen Hoang, Ruecker, Andrea, Amaratunga, Chanaki, Dhorda, Mehul, Miotto, Olivo, Maude, Richard J, Rekol, Huy, Chotivanich, Kesinee, Tarning, Joel, von Seidlein, Lorenz, Imwong, Mallika, Mukaka, Mavuto, Day, Nicholas P J, Hien, Tran Tinh, White, Nicholas J, and Dondorp, Arjen M

Published
2022
Full Text
View/download PDF

8. Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis.

Author

Fadilah, Ihsan, Commons, Robert J., Chau, Nguyen Hoang, Chu, Cindy S., Day, Nicholas P. J., Koh, Gavin C. K. W., Green, Justin A., Lacerda, Marcus VG, Llanos-Cuentas, Alejandro, Nelwan, Erni J., Nosten, Francois, Pasaribu, Ayodhia Pitaloka, Sutanto, Inge, Taylor, Walter R. J., Thriemer, Kamala, Price, Ric N., White, Nicholas J., Baird, J. Kevin, and Watson, James A.

Subjects
GLUCOSE-6-phosphate dehydrogenase, TREATMENT effectiveness, PLASMODIUM vivax, DRUG efficacy, BIOMARKERS
Abstract

Background: The 8-aminoquinolines, primaquine and tafenoquine, are the only available drugs for the radical cure of Plasmodium vivax hypnozoites. Previous evidence suggests that there is dose-dependent 8-aminoquinoline induced methaemoglobinaemia and that higher methaemoglobin concentrations are associated with a lower risk of P. vivax recurrence. We undertook a systematic review and individual patient data meta-analysis to examine the utility of methaemoglobin as a population-level surrogate endpoint for 8-aminoquinoline antihypnozoite activity to prevent P. vivax recurrence. Methods and findings: We conducted a systematic search of Medline, Embase, Web of Science, and the Cochrane Library, from 1 January 2000 to 29 September 2022, inclusive, of prospective clinical efficacy studies of acute, uncomplicated P. vivax malaria mono-infections treated with radical curative doses of primaquine. The day 7 methaemoglobin concentration was the primary surrogate outcome of interest. The primary clinical outcome was the time to first P. vivax recurrence between day 7 and day 120 after enrolment. We used multivariable Cox proportional-hazards regression with site random-effects to characterise the time to first recurrence as a function of the day 7 methaemoglobin percentage (log base 2 transformed), adjusted for the partner schizonticidal drug, the primaquine regimen duration as a proxy for the total primaquine dose (mg base/kg), the daily primaquine dose (mg/kg), and other factors. The systematic review protocol was registered with PROSPERO (CRD42023345956). We identified 219 P. vivax efficacy studies, of which 8 provided relevant individual-level data from patients treated with primaquine; all were randomised, parallel arm clinical trials assessed as having low or moderate risk of bias. In the primary analysis data set, there were 1,747 patients with normal glucose-6-phosphate dehydrogenase (G6PD) activity enrolled from 24 study sites across 8 different countries (Indonesia, Brazil, Vietnam, Thailand, Peru, Colombia, Ethiopia, and India). We observed an increasing dose-response relationship between the daily weight-adjusted primaquine dose and day 7 methaemoglobin level. For a given primaquine dose regimen, an observed doubling in day 7 methaemoglobin percentage was associated with an estimated 30% reduction in the risk of P. vivax recurrence (adjusted hazard ratio = 0.70; 95% confidence interval [CI] [0.57, 0.86]; p = 0.0005). These pooled estimates were largely consistent across the study sites. Using day 7 methaemoglobin as a surrogate endpoint for recurrence would reduce required sample sizes by approximately 40%. Study limitations include the inability to distinguish between recrudescence, reinfection, and relapse in P. vivax recurrences. Conclusions: For a given primaquine regimen, higher methaemoglobin on day 7 was associated with a reduced risk of P. vivax recurrence. Under our proposed causal model, this justifies the use of methaemoglobin as a population-level surrogate endpoint for primaquine antihypnozoite activity in patients with P. vivax malaria who have normal G6PD activity. Ihsan Fadilah and colleagues conduct an individual patient data meta-analysis examining the utility and validity of blood methaemoglobin as a surrogate endpoint for recurrent vivax malaria. Author summary: Why was this study done?: Plasmodium vivax causes recurrent malaria due to dormant liver stage parasites. The pro-drugs primaquine and tafenoquine are the only available treatments to prevent relapsing malaria, but their optimal dosing remains unclear. The active metabolites of primaquine and tafenoquine cause predictable increases in blood methaemoglobin; these same metabolites also kill liver parasites. This suggests that increases in blood methaemoglobin could be used as a population-level surrogate endpoint for liver stage parasite killing. What did the researchers do and find?: We conducted an individual patient data meta-analysis examining the utility and validity of blood methaemoglobin as a surrogate endpoint for recurrent vivax malaria. We systematically reviewed and pooled the available methaemoglobin and clinical data from patients with P. vivax malaria treated with primaquine over the last 20 years. We fit statistical models to these data to quantify the relationship between day 7 methaemoglobin levels and the risk of recurrent P. vivax malaria. We observed an increasing dose-response relationship between weight-adjusted primaquine dose and methaemoglobin levels measured on day 7. We found that for a fixed primaquine dose regimen, a doubling in day 7 methaemoglobin was associated with an estimated 30% reduction in the risk of vivax recurrence. Using day 7 methaemoglobin levels as a surrogate endpoint for recurrent malaria could reduce sample sizes needed in future studies by about 40% and reduce follow-up duration by 94%. What do these findings mean?: Patients with higher methaemoglobin levels a week after starting primaquine treatment appear to have a lower risk of recurrence. Day 7 methaemoglobin levels can potentially be used as a proxy for later vivax recurrence in exploratory trials, making it more efficient (e.g., fewer volunteers and resources required) to determine whether new drugs or regimens are effective. Study limitations include the inability to determine whether P. vivax recurrences are due to treatment failure, reinfection, or relapse. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study

Author

van der Pluijm, Rob W, Imwong, Mallika, Chau, Nguyen Hoang, Hoa, Nhu Thi, Thuy-Nhien, Nguyen Thanh, Thanh, Ngo Viet, Jittamala, Podjanee, Hanboonkunupakarn, Borimas, Chutasmit, Kitipumi, Saelow, Chalermpon, Runjarern, Ratchadaporn, Kaewmok, Weerayuth, Tripura, Rupam, Peto, Thomas J, Yok, Sovann, Suon, Seila, Sreng, Sokunthea, Mao, Sivanna, Oun, Savuth, Yen, Sovannary, Amaratunga, Chanaki, Lek, Dysoley, Huy, Rekol, Dhorda, Mehul, Chotivanich, Kesinee, Ashley, Elizabeth A, Mukaka, Mavuto, Waithira, Naomi, Cheah, Phaik Yeong, Maude, Richard J, Amato, Roberto, Pearson, Richard D, Gonçalves, Sónia, Jacob, Christopher G, Hamilton, William L, Fairhurst, Rick M, Tarning, Joel, Winterberg, Markus, Kwiatkowski, Dominic P, Pukrittayakamee, Sasithon, Hien, Tran Tinh, Day, Nicholas PJ, Miotto, Olivo, White, Nicholas J, and Dondorp, Arjen M

Published
2019
Full Text
View/download PDF

10. Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study

Author

Hamilton, William L, Amato, Roberto, van der Pluijm, Rob W, Jacob, Christopher G, Quang, Huynh Hong, Thuy-Nhien, Nguyen Thanh, Hien, Tran Tinh, Hongvanthong, Bouasy, Chindavongsa, Keobouphaphone, Mayxay, Mayfong, Huy, Rekol, Leang, Rithea, Huch, Cheah, Dysoley, Lek, Amaratunga, Chanaki, Suon, Seila, Fairhurst, Rick M, Tripura, Rupam, Peto, Thomas J, Sovann, Yok, Jittamala, Podjanee, Hanboonkunupakarn, Borimas, Pukrittayakamee, Sasithon, Chau, Nguyen Hoang, Imwong, Mallika, Dhorda, Mehul, Vongpromek, Ranitha, Chan, Xin Hui S, Maude, Richard J, Pearson, Richard D, Nguyen, T, Rockett, Kirk, Drury, Eleanor, Gonçalves, Sónia, White, Nicholas J, Day, Nicholas P, Kwiatkowski, Dominic P, Dondorp, Arjen M, and Miotto, Olivo

Published
2019
Full Text
View/download PDF

11. Case Series of Primaquine-Induced Haemolytic Events in Controlled Trials with G6PD Screening

Author

Kosasih, Ayleen, primary, James, Robert, additional, Chau, Nguyen Hoang, additional, Karman, Michelle M., additional, Panggalo, Lydia Visita, additional, Wini, Lyndes, additional, Thanh, Ngo Viet, additional, Obadia, Thomas, additional, Satyagraha, Ari Winasti, additional, Asih, Puji Budi Setia, additional, Syafruddin, Din, additional, Taylor, Walter R. J., additional, Mueller, Ivo, additional, Sutanto, Inge, additional, Karunajeewa, Harin, additional, Pasaribu, Ayodhia Pitaloka, additional, and Baird, J. Kevin, additional

Published
2023
Full Text
View/download PDF

12. Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency

Author

Taylor, Walter R. J., primary, Meagher, Niamh, additional, Ley, Benedikt, additional, Thriemer, Kamala, additional, Bancone, Germana, additional, Satyagraha, Ari, additional, Assefa, Ashenafi, additional, Chand, Krisin, additional, Chau, Nguyen Hoang, additional, Dhorda, Mehul, additional, Degaga, Tamiru S., additional, Ekawati, Lenny L., additional, Hailu, Asrat, additional, Hasanzai, Mohammad Anwar, additional, Naddim, Mohammad Nader, additional, Pasaribu, Ayodhia Pitaloka, additional, Rahim, Awab Ghulam, additional, Sutanto, Inge, additional, Thanh, Ngo Viet, additional, Tuyet-Trinh, Nguyen Thi, additional, Waithira, Naomi, additional, Woyessa, Adugna, additional, Dondorp, Arjen, additional, von Seidlein, Lorenz, additional, Simpson, Julie A., additional, White, Nicholas J., additional, Baird, J. Kevin, additional, Day, Nicholas P., additional, and Price, Ric N., additional

Published
2023
Full Text
View/download PDF

13. An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples

Author

Adam, Ishag, Alam, Mohammad Shafiul, Alemu, Sisay, Amaratunga, Chanaki, Amato, Roberto, Andrianaranjaka, Voahangy, Anstey, Nicholas M, Aseffa, Abraham, Ashley, Elizabeth, Assefa, Ashenafi, Auburn, Sarah, Barber, Bridget E, Barry, Alyssa, Batista Pereira, Dhelio, Cao, Jun, Chau, Nguyen Hoang, Chotivanich, Kesinee, Chu, Cindy, Dondorp, Arjen M, Drury, Eleanor, Echeverry, Diego F, Erko, Berhanu, Espino, Fe, Fairhurst, Rick, Faiz, Abdul, Fernanda Villegas, María, Gao, Qi, Golassa, Lemu, Goncalves, Sonia, Grigg, Matthew J, Hamedi, Yaghoob, Hien, Tran Tinh, Htut, Ye, Johnson, Kimberly J, Karunaweera, Nadira, Khan, Wasif, Krudsood, Srivicha, Kwiatkowski, Dominic P, Lacerda, Marcus, Ley, Benedikt, Lim, Pharath, Liu, Yaobao, Llanos-Cuentas, Alejandro, Lon, Chanthap, Lopera-Mesa, Tatiana, Marfurt, Jutta, Michon, Pascal, Miotto, Olivo, Mohammed, Rezika, Mueller, Ivo, Namaik-Larp, Chayadol, Newton, Paul N, Nguyen, Thuy-Nhien, Nosten, Francois, Noviyanti, Rintis, Pava, Zuleima, Pearson, Richard D, Petros, Beyene, Phyo, Aung P, Price, Ric N, Pukrittayakamee, Sasithon, Rahim, Awab Ghulam, Randrianarivelojosia, Milijaona, Rayner, Julian C, Rumaseb, Angela, Siegel, Sasha V, Simpson, Victoria J, Thriemer, Kamala, Tobon-Castano, Alberto, Trimarsanto, Hidayat, Urbano Ferreira, Marcelo, Vélez, Ivan D, Wangchuk, Sonam, Wellems, Thomas E, White, Nicholas J, William, Timothy, Yasnot, Maria F, Yilma, Daniel, Alam, Mohammad Shafiul [0000-0001-8330-5499], Ashley, Elizabeth [0000-0002-7620-4822], Barber, Bridget E [0000-0003-1066-7960], Batista Pereira, Dhelio [0000-0002-7761-5498], Chu, Cindy [0000-0001-9465-8214], Dondorp, Arjen M [0000-0001-5190-2395], Echeverry, Diego F [0000-0003-0301-4478], Espino, Fe [0000-0003-1690-1711], Faiz, Abdul [0000-0002-3460-7535], Golassa, Lemu [0000-0002-1216-8711], Grigg, Matthew J [0000-0001-9914-8352], Karunaweera, Nadira [0000-0003-3985-1817], Kwiatkowski, Dominic P [0000-0002-5023-0176], Ley, Benedikt [0000-0002-5734-0845], Miotto, Olivo [0000-0001-8060-6771], Nguyen, Thuy-Nhien [0000-0002-4101-5706], Nosten, Francois [0000-0002-7951-0745], Pearson, Richard D [0000-0002-7386-3566], Phyo, Aung P [0000-0002-0383-9624], Price, Ric N [0000-0003-2000-2874], Rayner, Julian C [0000-0002-9835-1014], Urbano Ferreira, Marcelo [0000-0002-5293-9090], Wellems, Thomas E [0000-0003-3899-8454], Yasnot, Maria F [0000-0001-8081-4212], Yilma, Daniel [0000-0001-6058-2696], and Apollo - University of Cambridge Repository

Subjects
parasitic diseases, Genomics, Genomic Epidemiology, Plasmodium vivax, Malaria, Data Resource
Abstract

This report describes the MalariaGEN Pv4 dataset, a new release of curated genome variation data on 1,895 samples of Plasmodium vivax collected at 88 worldwide locations between 2001 and 2017. It includes 1,370 new samples contributed by MalariaGEN and VivaxGEN partner studies in addition to previously published samples from these and other sources. We provide genotype calls at over 4.5 million variable positions including over 3 million single nucleotide polymorphisms (SNPs), as well as short indels and tandem duplications. This enlarged dataset highlights major compartments of parasite population structure, with clear differentiation between Africa, Latin America, Oceania, Western Asia and different parts of Southeast Asia. Each sample has been classified for drug resistance to sulfadoxine, pyrimethamine and mefloquine based on known markers at the dhfr, dhps and mdr1 loci. The prevalence of all of these resistance markers was much higher in Southeast Asia and Oceania than elsewhere. This open resource of analysis-ready genome variation data from the MalariaGEN and VivaxGEN networks is driven by our collective goal to advance research into the complex biology of P. vivax and to accelerate genomic surveillance for malaria control and elimination.

Published
2022

14. Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial

Author

Vélez, Iván D, primary, Hien, Tran T, additional, Green, Justin A, additional, Martin, Ana, additional, Sharma, Hema, additional, Rousell, Victoria M, additional, Breton, John J, additional, Ernest, Terry B, additional, Rolfe, Katie, additional, Taylor, Maxine, additional, Mohamed, Khadeeja, additional, Jones, Siôn W, additional, Chau, Nguyen Hoang, additional, Hoa, Nhu Thi, additional, Duparc, Stephan, additional, Tan, Lionel K, additional, and Goyal, Navin, additional

Published
2022
Full Text
View/download PDF

15. An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples

Author

MalariaGEN, Adam, Ishag, Alam, Mohammad Shafiul, Alemu, Sisay, Amaratunga, Chanaki, Amato, Roberto, Andrianaranjaka, Voahangy, Anstey, Nicholas M, Aseffa, Abraham, Ashley, Elizabeth, Assefa, Ashenafi, Auburn, Sarah, Barber, Bridget E, Barry, Alyssa, Batista Pereira, Dhelio, Cao, Jun, Chau, Nguyen Hoang, Chotivanich, Kesinee, Chu, Cindy, Dondorp, Arjen M, Drury, Eleanor, Echeverry, Diego F, Erko, Berhanu, Espino, Fe, Fairhurst, Rick, Faiz, Abdul, Fernanda Villegas, María, Gao, Qi, Golassa, Lemu, Goncalves, Sonia, Grigg, Matthew J, Hamedi, Yaghoob, Hien, Tran Tinh, Htut, Ye, Johnson, Kimberly J, Karunaweera, Nadira, Khan, Wasif, Krudsood, Srivicha, Kwiatkowski, Dominic P, Lacerda, Marcus, Ley, Benedikt, Lim, Pharath, Liu, Yaobao, Llanos-Cuentas, Alejandro, Lon, Chanthap, Lopera-Mesa, Tatiana, Marfurt, Jutta, Michon, Pascal, Miotto, Olivo, Mohammed, Rezika, Mueller, Ivo, Namaik-Larp, Chayadol, Newton, Paul N, Nguyen, Thuy-Nhien, Nosten, Francois, Noviyanti, Rintis, Pava, Zuleima, Pearson, Richard D, Petros, Beyene, Phyo, Aung P, Price, Ric N, Pukrittayakamee, Sasithon, Rahim, Awab Ghulam, Randrianarivelojosia, Milijaona, Rayner, Julian C, Rumaseb, Angela, Siegel, Sasha V, Simpson, Victoria J, Thriemer, Kamala, Tobon-Castano, Alberto, Trimarsanto, Hidayat, Urbano Ferreira, Marcelo, Vélez, Ivan D, Wangchuk, Sonam, Wellems, Thomas E, White, Nicholas J, William, Timothy, Yasnot, Maria F, Yilma, Daniel, AII - Infectious diseases, Intensive Care Medicine, MalariaGEN, Alam, Mohammad Shafiul [0000-0001-8330-5499], Ashley, Elizabeth [0000-0002-7620-4822], Barber, Bridget E [0000-0003-1066-7960], Batista Pereira, Dhelio [0000-0002-7761-5498], Chu, Cindy [0000-0001-9465-8214], Dondorp, Arjen M [0000-0001-5190-2395], Echeverry, Diego F [0000-0003-0301-4478], Espino, Fe [0000-0003-1690-1711], Faiz, Abdul [0000-0002-3460-7535], Golassa, Lemu [0000-0002-1216-8711], Karunaweera, Nadira [0000-0003-3985-1817], Kwiatkowski, Dominic P [0000-0002-5023-0176], Ley, Benedikt [0000-0002-5734-0845], Miotto, Olivo [0000-0001-8060-6771], Nguyen, Thuy-Nhien [0000-0002-4101-5706], Nosten, Francois [0000-0002-7951-0745], Pearson, Richard D [0000-0002-7386-3566], Phyo, Aung P [0000-0002-0383-9624], Price, Ric N [0000-0003-2000-2874], Rayner, Julian C [0000-0002-9835-1014], Urbano Ferreira, Marcelo [0000-0002-5293-9090], Wellems, Thomas E [0000-0003-3899-8454], Yasnot, Maria F [0000-0001-8081-4212], Yilma, Daniel [0000-0001-6058-2696], and Apollo - University of Cambridge Repository

Subjects
Data resource, parasitic diseases, Medicine (miscellaneous), Genomics, Genomic epidemiology, Plasmodium vivax, General Biochemistry, Genetics and Molecular Biology, Malaria
Abstract

This report describes the MalariaGEN Pv4 dataset, a new release of curated genome variation data on 1,895 samples of Plasmodium vivax collected at 88 worldwide locations between 2001 and 2017. It includes 1,370 new samples contributed by MalariaGEN and VivaxGEN partner studies in addition to previously published samples from these and other sources. We provide genotype calls at over 4.5 million variable positions including over 3 million single nucleotide polymorphisms (SNPs), as well as short indels and tandem duplications. This enlarged dataset highlights major compartments of parasite population structure, with clear differentiation between Africa, Latin America, Oceania, Western Asia and different parts of Southeast Asia. Each sample has been classified for drug resistance to sulfadoxine, pyrimethamine and mefloquine based on known markers at the dhfr, dhps and mdr1 loci. The prevalence of all of these resistance markers was much higher in Southeast Asia and Oceania than elsewhere. This open resource of analysis-ready genome variation data from the MalariaGEN and VivaxGEN networks is driven by our collective goal to advance research into the complex biology of P. vivax and to accelerate genomic surveillance for malaria control and elimination.

Published
2022

16. Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination

Author

Jacob, Christopher G, primary, Thuy-Nhien, Nguyen, additional, Mayxay, Mayfong, additional, Maude, Richard J, additional, Quang, Huynh Hong, additional, Hongvanthong, Bouasy, additional, Vanisaveth, Viengxay, additional, Ngo Duc, Thang, additional, Rekol, Huy, additional, van der Pluijm, Rob, additional, von Seidlein, Lorenz, additional, Fairhurst, Rick, additional, Nosten, François, additional, Hossain, Md Amir, additional, Park, Naomi, additional, Goodwin, Scott, additional, Ringwald, Pascal, additional, Chindavongsa, Keobouphaphone, additional, Newton, Paul, additional, Ashley, Elizabeth, additional, Phalivong, Sonexay, additional, Maude, Rapeephan, additional, Leang, Rithea, additional, Huch, Cheah, additional, Dong, Le Thanh, additional, Nguyen, Kim-Tuyen, additional, Nhat, Tran Minh, additional, Hien, Tran Tinh, additional, Nguyen, Hoa, additional, Zdrojewski, Nicole, additional, Canavati, Sara, additional, Sayeed, Abdullah Abu, additional, Uddin, Didar, additional, Buckee, Caroline, additional, Fanello, Caterina I, additional, Onyamboko, Marie, additional, Peto, Thomas, additional, Tripura, Rupam, additional, Amaratunga, Chanaki, additional, Myint Thu, Aung, additional, Delmas, Gilles, additional, Landier, Jordi, additional, Parker, Daniel M, additional, Chau, Nguyen Hoang, additional, Lek, Dysoley, additional, Suon, Seila, additional, Callery, James, additional, Jittamala, Podjanee, additional, Hanboonkunupakarn, Borimas, additional, Pukrittayakamee, Sasithon, additional, Phyo, Aung Pyae, additional, Smithuis, Frank, additional, Lin, Khin, additional, Thant, Myo, additional, Hlaing, Tin Maung, additional, Satpathi, Parthasarathi, additional, Satpathi, Sanghamitra, additional, Behera, Prativa K, additional, Tripura, Amar, additional, Baidya, Subrata, additional, Valecha, Neena, additional, Anvikar, Anupkumar R, additional, Ul Islam, Akhter, additional, Faiz, Abul, additional, Kunasol, Chanon, additional, Drury, Eleanor, additional, Kekre, Mihir, additional, Ali, Mozam, additional, Love, Katie, additional, Rajatileka, Shavanthi, additional, Jeffreys, Anna E, additional, Rowlands, Kate, additional, Hubbart, Christina S, additional, Dhorda, Mehul, additional, Vongpromek, Ranitha, additional, Kotanan, Namfon, additional, Wongnak, Phrutsamon, additional, Almagro Garcia, Jacob, additional, Pearson, Richard D, additional, Ariani, Cristina V, additional, Chookajorn, Thanat, additional, Malangone, Cinzia, additional, Nguyen, T, additional, Stalker, Jim, additional, Jeffery, Ben, additional, Keatley, Jonathan, additional, Johnson, Kimberly J, additional, Muddyman, Dawn, additional, Chan, Xin Hui S, additional, Sillitoe, John, additional, Amato, Roberto, additional, Simpson, Victoria, additional, Gonçalves, Sonia, additional, Rockett, Kirk, additional, Day, Nicholas P, additional, Dondorp, Arjen M, additional, Kwiatkowski, Dominic P, additional, and Miotto, Olivo, additional

Published
2021
Full Text
View/download PDF

17. Author response: Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination

Author

Jacob, Christopher G, primary, Thuy-Nhien, Nguyen, additional, Mayxay, Mayfong, additional, Maude, Richard J, additional, Quang, Huynh Hong, additional, Hongvanthong, Bouasy, additional, Vanisaveth, Viengxay, additional, Ngo Duc, Thang, additional, Rekol, Huy, additional, van der Pluijm, Rob, additional, von Seidlein, Lorenz, additional, Fairhurst, Rick, additional, Nosten, François, additional, Hossain, Md Amir, additional, Park, Naomi, additional, Goodwin, Scott, additional, Ringwald, Pascal, additional, Chindavongsa, Keobouphaphone, additional, Newton, Paul, additional, Ashley, Elizabeth, additional, Phalivong, Sonexay, additional, Maude, Rapeephan, additional, Leang, Rithea, additional, Huch, Cheah, additional, Dong, Le Thanh, additional, Nguyen, Kim-Tuyen, additional, Nhat, Tran Minh, additional, Hien, Tran Tinh, additional, Nguyen, Hoa, additional, Zdrojewski, Nicole, additional, Canavati, Sara, additional, Sayeed, Abdullah Abu, additional, Uddin, Didar, additional, Buckee, Caroline, additional, Fanello, Caterina I, additional, Onyamboko, Marie, additional, Peto, Thomas, additional, Tripura, Rupam, additional, Amaratunga, Chanaki, additional, Myint Thu, Aung, additional, Delmas, Gilles, additional, Landier, Jordi, additional, Parker, Daniel M, additional, Chau, Nguyen Hoang, additional, Lek, Dysoley, additional, Suon, Seila, additional, Callery, James, additional, Jittamala, Podjanee, additional, Hanboonkunupakarn, Borimas, additional, Pukrittayakamee, Sasithon, additional, Phyo, Aung Pyae, additional, Smithuis, Frank, additional, Lin, Khin, additional, Thant, Myo, additional, Hlaing, Tin Maung, additional, Satpathi, Parthasarathi, additional, Satpathi, Sanghamitra, additional, Behera, Prativa K, additional, Tripura, Amar, additional, Baidya, Subrata, additional, Valecha, Neena, additional, Anvikar, Anupkumar R, additional, Ul Islam, Akhter, additional, Faiz, Abul, additional, Kunasol, Chanon, additional, Drury, Eleanor, additional, Kekre, Mihir, additional, Ali, Mozam, additional, Love, Katie, additional, Rajatileka, Shavanthi, additional, Jeffreys, Anna E, additional, Rowlands, Kate, additional, Hubbart, Christina S, additional, Dhorda, Mehul, additional, Vongpromek, Ranitha, additional, Kotanan, Namfon, additional, Wongnak, Phrutsamon, additional, Almagro Garcia, Jacob, additional, Pearson, Richard D, additional, Ariani, Cristina V, additional, Chookajorn, Thanat, additional, Malangone, Cinzia, additional, Nguyen, T, additional, Stalker, Jim, additional, Jeffery, Ben, additional, Keatley, Jonathan, additional, Johnson, Kimberly J, additional, Muddyman, Dawn, additional, Chan, Xin Hui S, additional, Sillitoe, John, additional, Amato, Roberto, additional, Simpson, Victoria, additional, Gonçalves, Sonia, additional, Rockett, Kirk, additional, Day, Nicholas P, additional, Dondorp, Arjen M, additional, Kwiatkowski, Dominic P, additional, and Miotto, Olivo, additional

Published
2021
Full Text
View/download PDF

18. The mechanism of artemisinin resistance of Plasmodium falciparum malaria parasites originates in their initial transcriptional response.

Author

Zhu, Lei, primary, Pluijm, Rob W. van der, additional, Kucharski, Michal, additional, Nayak, Sourav, additional, Tripathi, Jaishree, additional, Nosten, François, additional, Faiz, Abul, additional, Amaratunga, Chanak, additional, Lek, Dysoley, additional, Ashley, Elizabeth A, additional, Smithuis, Frank, additional, Phyo, Aung Pyae, additional, Lin, Khin, additional, Imwong, Mallika, additional, Mayxay, Mayfong, additional, Dhorda, Mehul, additional, Chau, Nguyen Hoang, additional, Thuy, Nhien Nguyen Thanh Thuy, additional, Newton, Paul N, additional, Jittamala, Podjanee, additional, Tripura, Rupam, additional, Pukrittayakamee, Sasithon, additional, Peto, Thomas J, additional, Miotto, Olivo, additional, von Seidlein, Lorenz, additional, Hien, Tran Tinh, additional, Ginsburg, Hagai, additional, Day, Nicholas PJ, additional, White, Nicholas J., additional, Dondorp, Arjen M, additional, and Bozdech, Zbynek, additional

Published
2021
Full Text
View/download PDF

19. Genetic surveillance in the Greater Mekong Subregion and South Asia to support malaria control and elimination

Author

Jacob, Christopher G, primary, Thuy-Nhien, Nguyen, additional, Mayxay, Mayfong, additional, Maude, Richard J, additional, Quang, Huynh Hong, additional, Hongvanthong, Bouasy, additional, Vanisaveth, Viengxay, additional, Duc, Thang Ngo, additional, Rekol, Huy, additional, van der Pluijm, Rob W, additional, Von Seidlein, Lorenz, additional, Fairhurst, Rick M, additional, Nosten, Francois H, additional, Hossain, Md Amir, additional, Park, Naomi, additional, Goodwin, Scott, additional, Ringwald, Pascal, additional, Chindavongsa, Keobouphaphone, additional, Newton, Paul N, additional, Ashley, Elizabeth A, additional, Phalivong, Sonexay, additional, Maude, Rapeephan R, additional, Leang, Rithea, additional, Huch, Cheah, additional, Dong, Le Thanh, additional, Nguyen, Kim-Tuyen, additional, Nhat, Tran Minh, additional, Hien, Tran Tinh, additional, Nguyen, Hoa, additional, Zdrojewski, Nicole, additional, Canavati, Sara E, additional, Sayeed, Abdullah Abu, additional, Uddin, Didar, additional, Buckee, Caroline, additional, Fanello, Caterina I, additional, Onyamboko, Marie, additional, Peto, Thomas, additional, Tripura, Rupam, additional, Amaratunga, Chanaki, additional, Thu, Aung Myint, additional, Delmas, Gilles, additional, Landier, Jordi, additional, Parker, Daniel M, additional, Chau, Nguyen Hoang, additional, Lek, Dysoley, additional, Suon, Seila, additional, Callery, James J, additional, Jittamala, Podjanee, additional, Hanboonkunupakarn, Borimas, additional, Pukrittayakamee, Sasithon, additional, Phyo, Aung Pyae, additional, Smithuis, Frank, additional, Lin, Khin, additional, Thant, Myo, additional, Hlaing, Tin Maung, additional, Satpathi, Parthasarathi, additional, Satpathi, Sanghamitra, additional, Behera, Prativa K, additional, Tripura, Amar, additional, Baidya, Subrata, additional, Valecha, Neena, additional, Anvikar, Anupkumar R, additional, Islam, Akhter ul, additional, Faiz, Abul, additional, Kunasol, Chanon, additional, Drury, Eleanor, additional, Kekre, Mihir, additional, Ali, Mozam, additional, Love, Katie, additional, Rajatileka, Shavanthi, additional, Jeffreys, Anna E, additional, Rowlands, Kate, additional, Hubbart, Christina S, additional, Dhorda, Mehul, additional, Vongpromek, Ranitha, additional, Kotanan, Namfon, additional, Wongnak, Phrutsamon, additional, Garcia, Jacob Almagro, additional, Pearson, Richard D, additional, Ariani, Cristina V, additional, Chookajorn, Thanat, additional, Malangone, Cinzia, additional, Nguyen, T, additional, Stalker, Jim, additional, Jeffery, Ben, additional, Keatley, Jonathan, additional, Johnson, Kimberly J, additional, Muddyman, Dawn, additional, Chan, Xin Hui S, additional, Sillitoe, John, additional, Amato, Roberto, additional, Simpson, Victoria, additional, Gonçalves, Sonia, additional, Rockett, Kirk, additional, Day, Nicholas P, additional, Dondorp, Arjen M, additional, Kwiatkowski, Dominic P, additional, and Miotto, Olivo, additional

Published
2020
Full Text
View/download PDF

20. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial

Author

van der Pluijm, Rob W, primary, Tripura, Rupam, additional, Hoglund, Richard M, additional, Pyae Phyo, Aung, additional, Lek, Dysoley, additional, ul Islam, Akhter, additional, Anvikar, Anupkumar R, additional, Satpathi, Parthasarathi, additional, Satpathi, Sanghamitra, additional, Behera, Prativa Kumari, additional, Tripura, Amar, additional, Baidya, Subrata, additional, Onyamboko, Marie, additional, Chau, Nguyen Hoang, additional, Sovann, Yok, additional, Suon, Seila, additional, Sreng, Sokunthea, additional, Mao, Sivanna, additional, Oun, Savuth, additional, Yen, Sovannary, additional, Amaratunga, Chanaki, additional, Chutasmit, Kitipumi, additional, Saelow, Chalermpon, additional, Runcharern, Ratchadaporn, additional, Kaewmok, Weerayuth, additional, Hoa, Nhu Thi, additional, Thanh, Ngo Viet, additional, Hanboonkunupakarn, Borimas, additional, Callery, James J, additional, Mohanty, Akshaya Kumar, additional, Heaton, James, additional, Thant, Myo, additional, Gantait, Kripasindhu, additional, Ghosh, Tarapada, additional, Amato, Roberto, additional, Pearson, Richard D, additional, Jacob, Christopher G, additional, Gonçalves, Sónia, additional, Mukaka, Mavuto, additional, Waithira, Naomi, additional, Woodrow, Charles J, additional, Grobusch, Martin P, additional, van Vugt, Michele, additional, Fairhurst, Rick M, additional, Cheah, Phaik Yeong, additional, Peto, Thomas J, additional, von Seidlein, Lorenz, additional, Dhorda, Mehul, additional, Maude, Richard J, additional, Winterberg, Markus, additional, Thuy-Nhien, Nguyen Thanh, additional, Kwiatkowski, Dominic P, additional, Imwong, Mallika, additional, Jittamala, Podjanee, additional, Lin, Khin, additional, Hlaing, Tin Maung, additional, Chotivanich, Kesinee, additional, Huy, Rekol, additional, Fanello, Caterina, additional, Ashley, Elizabeth, additional, Mayxay, Mayfong, additional, Newton, Paul N, additional, Hien, Tran Tinh, additional, Valecha, Neena, additional, Smithuis, Frank, additional, Pukrittayakamee, Sasithon, additional, Faiz, Abul, additional, Miotto, Olivo, additional, Tarning, Joel, additional, Day, Nicholas P J, additional, White, Nicholas J, additional, Dondorp, Arjen M, additional, van der Pluijm, Rob W, additional, Phyo, Aung Pyae, additional, Thuy-Nhien, Nguyen T, additional, Valeche, Neena, additional, and Day, Nicholas PJ, additional

Published
2020
Full Text
View/download PDF

22. Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivaxmalaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial

Author

Vélez, Iván D, Hien, Tran T, Green, Justin A, Martin, Ana, Sharma, Hema, Rousell, Victoria M, Breton, John J, Ernest, Terry B, Rolfe, Katie, Taylor, Maxine, Mohamed, Khadeeja, Jones, Siôn W, Chau, Nguyen Hoang, Hoa, Nhu Thi, Duparc, Stephan, Tan, Lionel K, and Goyal, Navin

Abstract

Single-dose tafenoquine 300 mg is approved for Plasmodium vivaxmalaria relapse prevention in patients at least 16 years old. We aimed to determine appropriate oral tafenoquine paediatric dosing regimens, including a dispersible formulation, and evaluated tafenoquine efficacy and safety in children infected with P vivax.

Published
2022
Full Text
View/download PDF

23. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparummalaria: a multicentre, open-label, randomised clinical trial

Author

van der Pluijm, Rob W, Tripura, Rupam, Hoglund, Richard M, Pyae Phyo, Aung, Lek, Dysoley, ul Islam, Akhter, Anvikar, Anupkumar R, Satpathi, Parthasarathi, Satpathi, Sanghamitra, Behera, Prativa Kumari, Tripura, Amar, Baidya, Subrata, Onyamboko, Marie, Chau, Nguyen Hoang, Sovann, Yok, Suon, Seila, Sreng, Sokunthea, Mao, Sivanna, Oun, Savuth, Yen, Sovannary, Amaratunga, Chanaki, Chutasmit, Kitipumi, Saelow, Chalermpon, Runcharern, Ratchadaporn, Kaewmok, Weerayuth, Hoa, Nhu Thi, Thanh, Ngo Viet, Hanboonkunupakarn, Borimas, Callery, James J, Mohanty, Akshaya Kumar, Heaton, James, Thant, Myo, Gantait, Kripasindhu, Ghosh, Tarapada, Amato, Roberto, Pearson, Richard D, Jacob, Christopher G, Gonçalves, Sónia, Mukaka, Mavuto, Waithira, Naomi, Woodrow, Charles J, Grobusch, Martin P, van Vugt, Michele, Fairhurst, Rick M, Cheah, Phaik Yeong, Peto, Thomas J, von Seidlein, Lorenz, Dhorda, Mehul, Maude, Richard J, Winterberg, Markus, Thuy-Nhien, Nguyen Thanh, Kwiatkowski, Dominic P, Imwong, Mallika, Jittamala, Podjanee, Lin, Khin, Hlaing, Tin Maung, Chotivanich, Kesinee, Huy, Rekol, Fanello, Caterina, Ashley, Elizabeth, Mayxay, Mayfong, Newton, Paul N, Hien, Tran Tinh, Valecha, Neena, Smithuis, Frank, Pukrittayakamee, Sasithon, Faiz, Abul, Miotto, Olivo, Tarning, Joel, Day, Nicholas P J, White, Nicholas J, Dondorp, Arjen M, van der Pluijm, Rob W, Tripura, Rupam, Hoglund, Richard M, Phyo, Aung Pyae, Lek, Dysoley, ul Islam, Akhter, Anvikar, Anupkumar R, Satpathi, Parthasarathi, Satpathi, Sanghamitra, Behera, Prativa Kumari, Tripura, Amar, Baidya, Subrata, Onyamboko, Marie, Chau, Nguyen Hoang, Sovann, Yok, Suon, Seila, Sreng, Sokunthea, Mao, Sivanna, Oun, Savuth, Yen, Sovannary, Amaratunga, Chanaki, Chutasmit, Kitipumi, Saelow, Chalermpon, Runcharern, Ratchadaporn, Kaewmok, Weerayuth, Hoa, Nhu Thi, Thanh, Ngo Viet, Hanboonkunupakarn, Borimas, Callery, James J, Mohanty, Akshaya Kumar, Heaton, James, Thant, Myo, Gantait, Kripasindhu, Ghosh, Tarapada, Amato, Roberto, Pearson, Richard D, Jacob, Christopher G, Gonçalves, Sónia, Mukaka, Mavuto, Waithira, Naomi, Woodrow, Charles J, Grobusch, Martin P, van Vugt, Michele, Fairhurst, Rick M, Cheah, Phaik Yeong, Peto, Thomas J, von Seidlein, Lorenz, Dhorda, Mehul, Maude, Richard J, Winterberg, Markus, Thuy-Nhien, Nguyen T, Kwiatkowski, Dominic P, Imwong, Mallika, Jittamala, Podjanee, Lin, Khin, Hlaing, Tin Maung, Chotivanich, Kesinee, Huy, Rekol, Fanello, Caterina, Ashley, Elizabeth, Mayxay, Mayfong, Newton, Paul N, Hien, Tran Tinh, Valeche, Neena, Smithuis, Frank, Pukrittayakamee, Sasithon, Faiz, Abul, Miotto, Olivo, Tarning, Joel, Day, Nicholas PJ, White, Nicholas J, and Dondorp, Arjen M

Abstract

Artemisinin and partner-drug resistance in Plasmodium falciparumare major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance.

Published
2020
Full Text
View/download PDF

24. A molecular barcode and online tool to identify and map imported infection with Plasmodium vivax

Author

Trimarsanto, Hidayat, primary, Amato, Roberto, additional, Pearson, Richard D, additional, Sutanto, Edwin, additional, Noviyanti, Rintis, additional, Trianty, Leily, additional, Marfurt, Jutta, additional, Pava, Zuleima, additional, Echeverry, Diego F, additional, Lopera-Mesa, Tatiana M, additional, Montenegro, Lidia Madeline, additional, Tobón-Castaño, Alberto, additional, Grigg, Matthew J, additional, Barber, Bridget, additional, William, Timothy, additional, Anstey, Nicholas M, additional, Getachew, Sisay, additional, Petros, Beyene, additional, Aseffa, Abraham, additional, Assefa, Ashenafi, additional, Rahim, Awab Ghulam, additional, Chau, Nguyen Hoang, additional, Hien, Tran Tinh, additional, Alam, Mohammad Shafiul, additional, Khan, Wasif A, additional, Ley, Benedikt, additional, Thriemer, Kamala, additional, Wangchuck, Sonam, additional, Hamedi, Yaghoob, additional, Adam, Ishag, additional, Liu, Yaobao, additional, Gao, Qi, additional, Sriprawat, Kanlaya, additional, Ferreira, Marcelo U, additional, Barry, Alyssa, additional, Mueller, Ivo, additional, Drury, Eleanor, additional, Goncalves, Sonia, additional, Simpson, Victoria, additional, Miotto, Olivo, additional, Miles, Alistair, additional, White, Nicholas J, additional, Nosten, Francois, additional, Kwiatkowski, Dominic P, additional, Price, Ric N, additional, and Auburn, Sarah, additional

Published
2019
Full Text
View/download PDF

25. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial

Author

Taylor, Walter R J, primary, Thriemer, Kamala, additional, von Seidlein, Lorenz, additional, Yuentrakul, Prayoon, additional, Assawariyathipat, Thanawat, additional, Assefa, Ashenafi, additional, Auburn, Sarah, additional, Chand, Krisin, additional, Chau, Nguyen Hoang, additional, Cheah, Phaik Yeong, additional, Dong, Le Thanh, additional, Dhorda, Mehul, additional, Degaga, Tamiru Shibru, additional, Devine, Angela, additional, Ekawati, Lenny L, additional, Fahmi, Fahmi, additional, Hailu, Asrat, additional, Hasanzai, Mohammad Anwar, additional, Hien, Tran Tinh, additional, Khu, Htee, additional, Ley, Benedikt, additional, Lubell, Yoel, additional, Marfurt, Jutta, additional, Mohammad, Hussein, additional, Moore, Kerryn A, additional, Naddim, Mohammad Nader, additional, Pasaribu, Ayodhia Pitaloka, additional, Pasaribu, Syahril, additional, Promnarate, Cholrawee, additional, Rahim, Awab Ghulam, additional, Sirithiranont, Pasathron, additional, Solomon, Hiwot, additional, Sudoyo, Herawati, additional, Sutanto, Inge, additional, Thanh, Ngo Viet, additional, Tuyet-Trinh, Nguyen Thi, additional, Waithira, Naomi, additional, Woyessa, Adugna, additional, Yamin, Fazal Yamin, additional, Dondorp, Arjen, additional, Simpson, Julie A, additional, Baird, J Kevin, additional, White, Nicholas J, additional, Day, Nicholas P, additional, and Price, Ric N, additional

Published
2019
Full Text
View/download PDF

26. Evolution and expansion of multidrug resistant malaria in Southeast Asia: a genomic epidemiology study

Author

Hamilton, William L, primary, Amato, Roberto, additional, van der Pluijm, Rob W, additional, Jacob, Christopher G, additional, Quang, Huynh Hong, additional, Thuy-Nhien, Nguyen Thanh, additional, Hien, Tran Tinh, additional, Hongvanthong, Bouasy, additional, Chindavongsa, Keobouphaphone, additional, Mayxay, Mayfong, additional, Rekol, Huy, additional, Leang, Rithea, additional, Huch, Cheah, additional, Dysoley, Lek, additional, Amaratunga, Chanaki, additional, Suon, Seila, additional, Fairhurst, Rick M, additional, Tripura, Rupam, additional, Peto, Thomas J, additional, Sovann, Yok, additional, Jittamala, Podjanee, additional, Hanboonkunupakarn, Borimas, additional, Pukrittayakamee, Sasithon, additional, Chau, Nguyen Hoang, additional, Imwong, Mallika, additional, Dhorda, Mehul, additional, Vongpromek, Ranitha, additional, Chan, Xin Hui S, additional, Maude, Richard J, additional, Pearson, Richard D, additional, Nguyen, T, additional, Rockett, Kirk, additional, Drury, Eleanor, additional, Gonçalves, Sonia, additional, White, Nicholas J, additional, Day, Nicholas P, additional, Kwiatkowski, Dominic P, additional, Dondorp, Arjen M, additional, and Miotto, Olivo, additional

Published
2019
Full Text
View/download PDF

28. Short-course primaquine for the radical cure of Plasmodium vivaxmalaria: a multicentre, randomised, placebo-controlled non-inferiority trial

Author

Taylor, Walter R J, Thriemer, Kamala, von Seidlein, Lorenz, Yuentrakul, Prayoon, Assawariyathipat, Thanawat, Assefa, Ashenafi, Auburn, Sarah, Chand, Krisin, Chau, Nguyen Hoang, Cheah, Phaik Yeong, Dong, Le Thanh, Dhorda, Mehul, Degaga, Tamiru Shibru, Devine, Angela, Ekawati, Lenny L, Fahmi, Fahmi, Hailu, Asrat, Hasanzai, Mohammad Anwar, Hien, Tran Tinh, Khu, Htee, Ley, Benedikt, Lubell, Yoel, Marfurt, Jutta, Mohammad, Hussein, Moore, Kerryn A, Naddim, Mohammad Nader, Pasaribu, Ayodhia Pitaloka, Pasaribu, Syahril, Promnarate, Cholrawee, Rahim, Awab Ghulam, Sirithiranont, Pasathron, Solomon, Hiwot, Sudoyo, Herawati, Sutanto, Inge, Thanh, Ngo Viet, Tuyet-Trinh, Nguyen Thi, Waithira, Naomi, Woyessa, Adugna, Yamin, Fazal Yamin, Dondorp, Arjen, Simpson, Julie A, Baird, J Kevin, White, Nicholas J, Day, Nicholas P, and Price, Ric N

Abstract

Primaquine is the only widely used drug that prevents Plasmodium vivaxmalaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to assess the efficacy of a shorter course (7 days) of primaquine for radical cure of vivax malaria.

Published
2019
Full Text
View/download PDF

29. Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial

Author

Peto, Thomas J, Tripura, Rupam, Callery, James J, Lek, Dysoley, Nghia, Ho Dang Trung, Nguon, Chea, Thuong, Nguyen Thi Huyen, van der Pluijm, Rob W, Dung, Nguyen Thi Phuong, Sokha, Meas, Van Luong, Vo, Long, Le Thanh, Sovann, Yok, Duanguppama, Jureeporn, Waithira, Naomi, Hoglund, Richard M, Chotsiri, Palang, Chau, Nguyen Hoang, Ruecker, Andrea, Amaratunga, Chanaki, Dhorda, Mehul, Miotto, Olivo, Maude, Richard J, Rekol, Huy, Chotivanich, Kesinee, Tarning, Joel, von Seidlein, Lorenz, Imwong, Mallika, Mukaka, Mavuto, Day, Nicholas P J, Hien, Tran Tinh, White, Nicholas J, Dondorp, Arjen M, Peto, Thomas J, Tripura, Rupam, Callery, James J, Lek, Dysoley, Nghia, Ho Dang Trung, Nguon, Chea, Thuong, Nguyen Thi Huyen, van der Pluijm, Rob W, Dung, Nguyen Thi Phuong, Sokha, Meas, Van Luong, Vo, Long, Le Thanh, Sovann, Yok, Duanguppama, Jureeporn, Waithira, Naomi, Hoglund, Richard M, Chotsiri, Palang, Chau, Nguyen Hoang, Ruecker, Andrea, Amaratunga, Chanaki, Dhorda, Mehul, Miotto, Olivo, Maude, Richard J, Rekol, Huy, Chotivanich, Kesinee, Tarning, Joel, von Seidlein, Lorenz, Imwong, Mallika, Mukaka, Mavuto, Day, Nicholas P J, Hien, Tran Tinh, White, Nicholas J, and Dondorp, Arjen M

Abstract

Background: Late treatment failures after artemisinin-based combination therapies (ACTs) for falciparum malaria have increased in the Greater Mekong subregion in southeast Asia. Addition of amodiaquine to artemether-lumefantrine could provide an efficacious treatment for multidrug-resistant infections. Methods: We conducted an open-label, randomised trial at five hospitals or health centres in three locations (western Cambodia, eastern Cambodia, and Vietnam). Eligible participants were male and female patients aged 2-65 years with uncomplicated Plasmodium falciparum malaria. Patients were randomly allocated (1:1 in blocks of eight to 12) to either artemether-lumefantrine alone (dosed according to WHO guidelines) or artemether-lumefantrine plus amodiaquine (10 mg base per kg/day), both given orally as six doses over 3 days. All received a single dose of primaquine (0·25 mg/kg) 24 h after the start of study treatment to limit transmission of the parasite. Parasites were genotyped, identifying artemisinin resistance. The primary outcome was Kaplan-Meier 42-day PCR-corrected efficacy against recrudescence of the original parasite, assessed by intent-to-treat. Safety was a secondary outcome. This completed trial is registered at ClinicalTrials.gov (NCT03355664). Findings: Between March 18, 2018, and Jan 30, 2020, 310 patients received randomly allocated treatment; 154 received artemether-lumefantrine alone and 156 received artemether-lumefantrine plus amodiaquine. Parasites from 305 of these patients were genotyped. 42-day PCR-corrected treatment efficacy was noted in 151 (97%, 95% CI 92-99) of 156 patients with artemether-lumefantrine plus amodiaquine versus 146 (95%, 89-97) of 154 patients with artemether-lumefantrine alone; hazard ratio (HR) for recrudescence 0·6 (95% CI 0·2-1·9, p=0·38). Of the 13 recrudescences, 12 were in 174 (57%) of 305 infections with pfkelch13 mutations indicating artemisinin resistance, for which 42-day efficacy was noted in 89 (

30. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.

Author

van der Pluijm, Rob W, Tripura, Rupam, Hoglund, Richard M, Pyae Phyo, Aung, Lek, Dysoley, Ul Islam, Akhter, Anvikar, Anupkumar R, Satpathi, Parthasarathi, Satpathi, Sanghamitra, Behera, Prativa Kumari, Tripura, Amar, Baidya, Subrata, Onyamboko, Marie, Chau, Nguyen Hoang, Sovann, Yok, Suon, Seila, Sreng, Sokunthea, Mao, Sivanna, Oun, Savuth, Yen, Sovannary, Amaratunga, Chanaki, Chutasmit, Kitipumi, Saelow, Chalermpon, Runcharern, Ratchadaporn, Kaewmok, Weerayuth, Hoa, Nhu Thi, Thanh, Ngo Viet, Hanboonkunupakarn, Borimas, Callery, James J, Mohanty, Akshaya Kumar, Heaton, James, Thant, Myo, Gantait, Kripasindhu, Ghosh, Tarapada, Amato, Roberto, Pearson, Richard D, Jacob, Christopher G, Gonçalves, Sónia, Mukaka, Mavuto, Waithira, Naomi, Woodrow, Charles J, Grobusch, Martin P, van Vugt, Michele, Fairhurst, Rick M, Cheah, Phaik Yeong, Peto, Thomas J, von Seidlein, Lorenz, Dhorda, Mehul, Maude, Richard J, Winterberg, Markus, Thuy-Nhien, Nguyen Thanh, Kwiatkowski, Dominic P, Imwong, Mallika, Jittamala, Podjanee, Lin, Khin, Hlaing, Tin Maung, Chotivanich, Kesinee, Huy, Rekol, Fanello, Caterina, Ashley, Elizabeth, Mayxay, Mayfong, Newton, Paul N, Hien, Tran Tinh, Valecha, Neena, Smithuis, Frank, Pukrittayakamee, Sasithon, Faiz, Abul, Miotto, Olivo, Tarning, Joel, Day, Nicholas P J, White, Nicholas J, Dondorp, Arjen M, van der Pluijm, Rob W, Tripura, Rupam, Hoglund, Richard M, Pyae Phyo, Aung, Lek, Dysoley, Ul Islam, Akhter, Anvikar, Anupkumar R, Satpathi, Parthasarathi, Satpathi, Sanghamitra, Behera, Prativa Kumari, Tripura, Amar, Baidya, Subrata, Onyamboko, Marie, Chau, Nguyen Hoang, Sovann, Yok, Suon, Seila, Sreng, Sokunthea, Mao, Sivanna, Oun, Savuth, Yen, Sovannary, Amaratunga, Chanaki, Chutasmit, Kitipumi, Saelow, Chalermpon, Runcharern, Ratchadaporn, Kaewmok, Weerayuth, Hoa, Nhu Thi, Thanh, Ngo Viet, Hanboonkunupakarn, Borimas, Callery, James J, Mohanty, Akshaya Kumar, Heaton, James, Thant, Myo, Gantait, Kripasindhu, Ghosh, Tarapada, Amato, Roberto, Pearson, Richard D, Jacob, Christopher G, Gonçalves, Sónia, Mukaka, Mavuto, Waithira, Naomi, Woodrow, Charles J, Grobusch, Martin P, van Vugt, Michele, Fairhurst, Rick M, Cheah, Phaik Yeong, Peto, Thomas J, von Seidlein, Lorenz, Dhorda, Mehul, Maude, Richard J, Winterberg, Markus, Thuy-Nhien, Nguyen Thanh, Kwiatkowski, Dominic P, Imwong, Mallika, Jittamala, Podjanee, Lin, Khin, Hlaing, Tin Maung, Chotivanich, Kesinee, Huy, Rekol, Fanello, Caterina, Ashley, Elizabeth, Mayxay, Mayfong, Newton, Paul N, Hien, Tran Tinh, Valecha, Neena, Smithuis, Frank, Pukrittayakamee, Sasithon, Faiz, Abul, Miotto, Olivo, Tarning, Joel, Day, Nicholas P J, White, Nicholas J, and Dondorp, Arjen M

Abstract

Background:Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance. Methods: In this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries. Eligible patients were aged 2-65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin-piperaquine or dihydroartemisinin-piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate-mefloquine or dihydroartemisinin-piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether-lumefantrine or artemether-lumefantrine plus amodiaquine. All drugs were administered orally and doses varied by drug combination and site. Patients were followed-up weekly for 42 days. The primary endpoint was efficacy, defined by 42-day PCR-corrected adequate clinical and parasitological response. Primary analysis was by intention to treat. A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment. This study is registered at ClinicalTrials.gov, NCT02453308, and is complete. Findings: Between Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin-piperaqui

31. Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial

Author

Peto, Thomas J, Tripura, Rupam, Callery, James J, Lek, Dysoley, Nghia, Ho Dang Trung, Nguon, Chea, Thuong, Nguyen Thi Huyen, van der Pluijm, Rob W, Dung, Nguyen Thi Phuong, Sokha, Meas, Van Luong, Vo, Long, Le Thanh, Sovann, Yok, Duanguppama, Jureeporn, Waithira, Naomi, Hoglund, Richard M, Chotsiri, Palang, Chau, Nguyen Hoang, Ruecker, Andrea, Amaratunga, Chanaki, Dhorda, Mehul, Miotto, Olivo, Maude, Richard J, Rekol, Huy, Chotivanich, Kesinee, Tarning, Joel, von Seidlein, Lorenz, Imwong, Mallika, Mukaka, Mavuto, Day, Nicholas P J, Hien, Tran Tinh, White, Nicholas J, Dondorp, Arjen M, Peto, Thomas J, Tripura, Rupam, Callery, James J, Lek, Dysoley, Nghia, Ho Dang Trung, Nguon, Chea, Thuong, Nguyen Thi Huyen, van der Pluijm, Rob W, Dung, Nguyen Thi Phuong, Sokha, Meas, Van Luong, Vo, Long, Le Thanh, Sovann, Yok, Duanguppama, Jureeporn, Waithira, Naomi, Hoglund, Richard M, Chotsiri, Palang, Chau, Nguyen Hoang, Ruecker, Andrea, Amaratunga, Chanaki, Dhorda, Mehul, Miotto, Olivo, Maude, Richard J, Rekol, Huy, Chotivanich, Kesinee, Tarning, Joel, von Seidlein, Lorenz, Imwong, Mallika, Mukaka, Mavuto, Day, Nicholas P J, Hien, Tran Tinh, White, Nicholas J, and Dondorp, Arjen M

Abstract

Background: Late treatment failures after artemisinin-based combination therapies (ACTs) for falciparum malaria have increased in the Greater Mekong subregion in southeast Asia. Addition of amodiaquine to artemether-lumefantrine could provide an efficacious treatment for multidrug-resistant infections. Methods: We conducted an open-label, randomised trial at five hospitals or health centres in three locations (western Cambodia, eastern Cambodia, and Vietnam). Eligible participants were male and female patients aged 2-65 years with uncomplicated Plasmodium falciparum malaria. Patients were randomly allocated (1:1 in blocks of eight to 12) to either artemether-lumefantrine alone (dosed according to WHO guidelines) or artemether-lumefantrine plus amodiaquine (10 mg base per kg/day), both given orally as six doses over 3 days. All received a single dose of primaquine (0·25 mg/kg) 24 h after the start of study treatment to limit transmission of the parasite. Parasites were genotyped, identifying artemisinin resistance. The primary outcome was Kaplan-Meier 42-day PCR-corrected efficacy against recrudescence of the original parasite, assessed by intent-to-treat. Safety was a secondary outcome. This completed trial is registered at ClinicalTrials.gov (NCT03355664). Findings: Between March 18, 2018, and Jan 30, 2020, 310 patients received randomly allocated treatment; 154 received artemether-lumefantrine alone and 156 received artemether-lumefantrine plus amodiaquine. Parasites from 305 of these patients were genotyped. 42-day PCR-corrected treatment efficacy was noted in 151 (97%, 95% CI 92-99) of 156 patients with artemether-lumefantrine plus amodiaquine versus 146 (95%, 89-97) of 154 patients with artemether-lumefantrine alone; hazard ratio (HR) for recrudescence 0·6 (95% CI 0·2-1·9, p=0·38). Of the 13 recrudescences, 12 were in 174 (57%) of 305 infections with pfkelch13 mutations indicating artemisinin resistance, for which 42-day efficacy was noted in 89 (

32. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.

Author

van der Pluijm, Rob W, Tripura, Rupam, Hoglund, Richard M, Pyae Phyo, Aung, Lek, Dysoley, Ul Islam, Akhter, Anvikar, Anupkumar R, Satpathi, Parthasarathi, Satpathi, Sanghamitra, Behera, Prativa Kumari, Tripura, Amar, Baidya, Subrata, Onyamboko, Marie, Chau, Nguyen Hoang, Sovann, Yok, Suon, Seila, Sreng, Sokunthea, Mao, Sivanna, Oun, Savuth, Yen, Sovannary, Amaratunga, Chanaki, Chutasmit, Kitipumi, Saelow, Chalermpon, Runcharern, Ratchadaporn, Kaewmok, Weerayuth, Hoa, Nhu Thi, Thanh, Ngo Viet, Hanboonkunupakarn, Borimas, Callery, James J, Mohanty, Akshaya Kumar, Heaton, James, Thant, Myo, Gantait, Kripasindhu, Ghosh, Tarapada, Amato, Roberto, Pearson, Richard D, Jacob, Christopher G, Gonçalves, Sónia, Mukaka, Mavuto, Waithira, Naomi, Woodrow, Charles J, Grobusch, Martin P, van Vugt, Michele, Fairhurst, Rick M, Cheah, Phaik Yeong, Peto, Thomas J, von Seidlein, Lorenz, Dhorda, Mehul, Maude, Richard J, Winterberg, Markus, Thuy-Nhien, Nguyen Thanh, Kwiatkowski, Dominic P, Imwong, Mallika, Jittamala, Podjanee, Lin, Khin, Hlaing, Tin Maung, Chotivanich, Kesinee, Huy, Rekol, Fanello, Caterina, Ashley, Elizabeth, Mayxay, Mayfong, Newton, Paul N, Hien, Tran Tinh, Valecha, Neena, Smithuis, Frank, Pukrittayakamee, Sasithon, Faiz, Abul, Miotto, Olivo, Tarning, Joel, Day, Nicholas P J, White, Nicholas J, Dondorp, Arjen M, van der Pluijm, Rob W, Tripura, Rupam, Hoglund, Richard M, Pyae Phyo, Aung, Lek, Dysoley, Ul Islam, Akhter, Anvikar, Anupkumar R, Satpathi, Parthasarathi, Satpathi, Sanghamitra, Behera, Prativa Kumari, Tripura, Amar, Baidya, Subrata, Onyamboko, Marie, Chau, Nguyen Hoang, Sovann, Yok, Suon, Seila, Sreng, Sokunthea, Mao, Sivanna, Oun, Savuth, Yen, Sovannary, Amaratunga, Chanaki, Chutasmit, Kitipumi, Saelow, Chalermpon, Runcharern, Ratchadaporn, Kaewmok, Weerayuth, Hoa, Nhu Thi, Thanh, Ngo Viet, Hanboonkunupakarn, Borimas, Callery, James J, Mohanty, Akshaya Kumar, Heaton, James, Thant, Myo, Gantait, Kripasindhu, Ghosh, Tarapada, Amato, Roberto, Pearson, Richard D, Jacob, Christopher G, Gonçalves, Sónia, Mukaka, Mavuto, Waithira, Naomi, Woodrow, Charles J, Grobusch, Martin P, van Vugt, Michele, Fairhurst, Rick M, Cheah, Phaik Yeong, Peto, Thomas J, von Seidlein, Lorenz, Dhorda, Mehul, Maude, Richard J, Winterberg, Markus, Thuy-Nhien, Nguyen Thanh, Kwiatkowski, Dominic P, Imwong, Mallika, Jittamala, Podjanee, Lin, Khin, Hlaing, Tin Maung, Chotivanich, Kesinee, Huy, Rekol, Fanello, Caterina, Ashley, Elizabeth, Mayxay, Mayfong, Newton, Paul N, Hien, Tran Tinh, Valecha, Neena, Smithuis, Frank, Pukrittayakamee, Sasithon, Faiz, Abul, Miotto, Olivo, Tarning, Joel, Day, Nicholas P J, White, Nicholas J, and Dondorp, Arjen M

Abstract

Background:Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance. Methods: In this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries. Eligible patients were aged 2-65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin-piperaquine or dihydroartemisinin-piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate-mefloquine or dihydroartemisinin-piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether-lumefantrine or artemether-lumefantrine plus amodiaquine. All drugs were administered orally and doses varied by drug combination and site. Patients were followed-up weekly for 42 days. The primary endpoint was efficacy, defined by 42-day PCR-corrected adequate clinical and parasitological response. Primary analysis was by intention to treat. A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment. This study is registered at ClinicalTrials.gov, NCT02453308, and is complete. Findings: Between Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin-piperaqui

33. Lineage-informative microhaplotypes for spatio-temporal surveillance of Plasmodium vivax malaria parasites.

Author

Siegel SV, Amato R, Trimarsanto H, Sutanto E, Kleinecke M, Murie K, Whitton G, Taylor AR, Watson JA, Imwong M, Assefa A, Rahim AG, Chau NH, Hien TT, Green JA, Koh G, White NJ, Day N, Kwiatkowski DP, Rayner JC, Price RN, and Auburn S

Abstract

Challenges in understanding the origin of recurrent Plasmodium vivax infections constrains the surveillance of antimalarial efficacy and transmission of this neglected parasite. Recurrent infections within an individual may arise from activation of dormant liver stages (relapse), blood-stage treatment failure (recrudescence) or new inoculations (reinfection). Molecular inference of familial relatedness (identity-by-descent or IBD) based on whole genome sequence data, together with analysis of the intervals between parasitaemic episodes ("time-to-event" analysis), can help resolve the probable origin of recurrences. Whole genome sequencing of predominantly low-density P. vivax infections is challenging, so an accurate and scalable genotyping method to determine the origins of recurrent parasitaemia would be of significant benefit. We have developed a P. vivax genome-wide informatics pipeline to select specific microhaplotype panels that can capture IBD within small, amplifiable segments of the genome. Using a global set of 615 P. vivax genomes, we derived a panel of 100 microhaplotypes, each comprising 3-10 high frequency SNPs within <200 bp sequence windows. This panel exhibits high diversity in regions of the Asia-Pacific, Latin America and the horn of Africa (median H E = 0.70-0.81) and it captured 89% (273/307) of the polyclonal infections detected with genome-wide datasets. Using data simulations, we demonstrate lower error in estimating pairwise IBD using microhaplotypes, relative to traditional biallelic SNP barcodes. Our panel exhibited high accuracy in predicting the country of origin (median Matthew's correlation coefficient >0.9 in 90% countries tested) and it also captured local infection outbreak and bottlenecking events. The informatics pipeline is available open-source and yields microhaplotypes that can be readily transferred to high-throughput amplicon sequencing assays for surveillance in malaria-endemic regions.

Published
2023
Full Text
View/download PDF

34. An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples.

Author

Adam I, Alam MS, Alemu S, Amaratunga C, Amato R, Andrianaranjaka V, Anstey NM, Aseffa A, Ashley E, Assefa A, Auburn S, Barber BE, Barry A, Batista Pereira D, Cao J, Chau NH, Chotivanich K, Chu C, Dondorp AM, Drury E, Echeverry DF, Erko B, Espino F, Fairhurst R, Faiz A, Fernanda Villegas M, Gao Q, Golassa L, Goncalves S, Grigg MJ, Hamedi Y, Hien TT, Htut Y, Johnson KJ, Karunaweera N, Khan W, Krudsood S, Kwiatkowski DP, Lacerda M, Ley B, Lim P, Liu Y, Llanos-Cuentas A, Lon C, Lopera-Mesa T, Marfurt J, Michon P, Miotto O, Mohammed R, Mueller I, Namaik-Larp C, Newton PN, Nguyen TN, Nosten F, Noviyanti R, Pava Z, Pearson RD, Petros B, Phyo AP, Price RN, Pukrittayakamee S, Rahim AG, Randrianarivelojosia M, Rayner JC, Rumaseb A, Siegel SV, Simpson VJ, Thriemer K, Tobon-Castano A, Trimarsanto H, Urbano Ferreira M, Vélez ID, Wangchuk S, Wellems TE, White NJ, William T, Yasnot MF, and Yilma D

Abstract

This report describes the MalariaGEN Pv4 dataset, a new release of curated genome variation data on 1,895 samples of Plasmodium vivax collected at 88 worldwide locations between 2001 and 2017. It includes 1,370 new samples contributed by MalariaGEN and VivaxGEN partner studies in addition to previously published samples from these and other sources. We provide genotype calls at over 4.5 million variable positions including over 3 million single nucleotide polymorphisms (SNPs), as well as short indels and tandem duplications. This enlarged dataset highlights major compartments of parasite population structure, with clear differentiation between Africa, Latin America, Oceania, Western Asia and different parts of Southeast Asia. Each sample has been classified for drug resistance to sulfadoxine, pyrimethamine and mefloquine based on known markers at the dhfr , dhps and mdr1 loci. The prevalence of all of these resistance markers was much higher in Southeast Asia and Oceania than elsewhere. This open resource of analysis-ready genome variation data from the MalariaGEN and VivaxGEN networks is driven by our collective goal to advance research into the complex biology of P. vivax and to accelerate genomic surveillance for malaria control and elimination., Competing Interests: No competing interests were disclosed., (Copyright: © 2022 MalariaGEN et al.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results